THIRD AMENDMENT TO LICENSE AGREEMENTLicense Agreement • March 9th, 2023 • Prime Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
THIS THIRD AMENDMENT TO LICENSE AGREEMENT (this “Amendment”) is made as of December 22, 2022 (the “Amendment Effective Date”), by and between The Broad Institute, Inc. (“Broad”) and Prime Medicine, Inc. (“Company”). Capitalized terms used herein but not defined herein shall have the same meaning as set forth in the License Agreement (as defined below). Each of Broad and Company may be referred to herein as a “Party” or together as the “Parties.”
